Catalent has signed an agreement with Cybin, Inc., a Canadian biotech company focused on progressing psychedelic therapeutics, to apply Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology for the delivery of Cybin’s novel deuterated tryptamine (CYB003), a potential therapy for treatment-resistant psychiatric disorders.   Zydis technology creates a freeze-dried tablet that disperses almost instantly in the mouth without water. Delivering CYB003 in such a dose form could h...